Troax Group’s Q1 2026 results

Order intake rose 18% year over year to 82.0 MEUR in January–March, but fell 5% on an organic basis after adjusting for currency and acquisitions. Management said market demand remains difficult to assess and relatively weak, though it improved toward the end of the quarter and recent acquisitions boosted orders and invoicing. The update is mixed, with headline growth offset by underlying softness.

Analysis

The key read-through is not the headline growth, but the split between reported and organic orders: acquired revenue is masking underlying softness. That usually creates a lagging P&L tailwind for 1-2 quarters, then a margin problem once integration costs and lower-quality acquired mix show up, especially if the core book is still contracting in the high single digits on a constant-currency basis. In practice, that means competitors with less M&A support and more exposed to end-demand will likely show cleaner deterioration than this name, so the whole peer set may be less attractive on a relative basis than the headline print suggests.

The late-quarter improvement is the part worth watching, because it can be a real inflection or just end-of-period project timing. If it reflects customer destocking ending, the upside can persist into the next quarter; if it is merely order pushout from customers protecting budgets, the quarter-over-quarter cadence will flatten again quickly. The distinction matters over a 4-8 week horizon because this is a business where backlog quality often leads reported revenue by only one or two reporting periods.

The contrarian takeaway is that the market may be underestimating how much current growth is non-organic, which can support near-term valuation but cap medium-term multiple expansion. The setup is more favorable for a relative-value trade than a directional long: the business can look resilient in reported numbers while the true demand environment stays weak. If the next update does not confirm a broader organic inflection, expect the M&A premium to compress first, before the headline earnings do.

Key Decisions for Investors

• Avoid chasing the stock on the headline order growth; if you want exposure, wait 1-2 quarters for evidence that organic orders stop contracting before paying up for the reported growth.
• Relative-value short: short this name against a peer with less acquisition support and more organic exposure; hold for the next earnings cycle and target multiple compression if organic orders remain negative.
• If the equity is already owned, consider selling covered calls 1-2 months out to monetize the near-term support from acquisition-driven revenue while capping upside into the next print.
• Watch for a confirmation catalyst in the next quarter's order intake mix; if organic growth turns positive, reassess for a tactical long, but only with a tight stop if end-market demand fails to broaden.